Zydus Lifesciences Ltd has received approval from China’s National Medical Products Administration (NMPA) to market Venlafaxine extended-release capsules in 75 mg and 150 mg strengths.
First Approval in China
This marks Zydus Lifesciences’ first regulatory approval in China, representing a key milestone in the company’s expansion into the Chinese pharmaceutical market, particularly in the mental health segment.
Product and Indications
Venlafaxine ER capsules are prescribed for the treatment of:
- Major depressive disorder
- Generalised anxiety disorder
- Social anxiety disorder
- Panic disorder
The medication works by balancing serotonin and norepinephrine levels in the brain, helping stabilise mood and alleviate symptoms of anxiety.
Strategic Expansion
With this approval, Zydus will be able to market and distribute the drug in China, expanding access to affordable treatment options for mental health conditions. The development also strengthens the company’s presence in regulated international markets beyond the United States and Europe, with a growing focus on the Asia-Pacific region.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.